An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165 (Prism301)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01819727
Recruitment Status : Completed
First Posted : March 28, 2013
Last Update Posted : August 21, 2017
Information provided by (Responsible Party):
BioMarin Pharmaceutical

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : November 2015
  Study Completion Date : December 2016
  Certification/Extension First Submitted : August 17, 2017